SMARCA1 and cancer: Recently, we and others have reported that SWI/SNF deficiency is related to sensitivity to immune checkpoint blockade (ICB) therapy, indicating the potential for use of the SWI/SNF complex as a target for cancer immunotherapy6,26–29.